scholarly journals MMP7 interacts with ARF in nucleus to potentiate tumor microenvironments for prostate cancer progression in vivo

Oncotarget ◽  
2016 ◽  
Vol 7 (30) ◽  
pp. 47609-47619 ◽  
Author(s):  
Yingqiu Xie ◽  
Wenfu Lu ◽  
Shenji Liu ◽  
Qing Yang ◽  
J. Shawn Goodwin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Cancer Progression ◽  
Tumor Microenvironments

scholarly journals In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun

Oncogene ◽  
2021 ◽  
Vol 40 (13) ◽  
pp. 2437-2447
Author(s):  
Maria Riedel ◽  
Martin F. Berthelsen ◽  
Huiqiang Cai ◽  
Jakob Haldrup ◽  
Michael Borre ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Cancer Progression

scholarly journals CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo

2020 ◽  
Vol 130 (5) ◽  
pp. 2435-2450
Author(s):  
Abdullah Alajati ◽  
Mariantonietta D’Ambrosio ◽  
Martina Troiani ◽  
Simone Mosole ◽  
Laura Pellegrini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Cancer Progression

scholarly journals Embigin Promotes Prostate Cancer Progression by S100A4-Dependent and-Independent Mechanisms

Cancers ◽  
2018 ◽  
Vol 10 (7) ◽  
pp. 239 ◽  
Author(s):  
I Ruma ◽  
Rie Kinoshita ◽  
Nahoko Tomonobu ◽  
Yusuke Inoue ◽  
Eisaku Kondo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Immunoglobulin Superfamily ◽  
Prostate Cancer Progression ◽  
Transmembrane Glycoprotein ◽  
Mtorc1 Signaling ◽  
Ampk Activity ◽  
In Vivo Growth

Embigin, a transmembrane glycoprotein belonging to the immunoglobulin superfamily, is involved in prostate and mammary gland development. As embigin’s roles in cancer remain elusive, we studied its biological functions and interaction with extracellular S100A4 in prostate cancer progression. We found by a pull-down assay that embigin is a novel receptor for S100A4, which is one of the vital cancer microenvironment milleu. Binding of extracellular S100A4 to embigin mediates prostate cancer progression by inhibition of AMPK activity, activation of NF-κB, MMP9 and mTORC1 signaling, and inhibition of autophagy, which increase prostate cancer cell motility. We also found that embigin promotes prostate cancer growth, spheroid- and colony-forming ability, and survival upon chemotherapy independently of S100A4. An in vivo growth mouse model confirmed the importance of embigin and its cytoplasmic tail in mediating prostate tumor growth. Moreover, embigin and p21WAF1 can be used to predict survival of prostate cancer patients. Our results demonstrated for the first time that the S100A4-embigin/AMPK/mTORC1/p21WAF1 and NF-κB/MMP9 axis is a vital oncogenic molecular cascade for prostate cancer progression. We proposed that embigin and p21WAF1 could be used as prognostic biomarkers and a strategy to inhibit S100A4-embigin binding could be a therapeutic approach for prostate cancer patients.

scholarly journals Knockdown of GSG2 inhibits prostate cancer progression in�vitro and in�vivo

2020 ◽  
Author(s):  
Feng Yu ◽  
Yuanyuan Lin ◽  
Xinping Xu ◽  
Weipeng Liu ◽  
Dan Tang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Cancer Progression

1617 SUSTAINED AEROBIC EXERCISE ALONE DOES NOT COUNTERACT THE TUMOR-PROMOTING EFFECTS OF A WESTERNIZED DIET ON PROSTATE CANCER PROGRESSION IN VIVO

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Natalie Venier ◽  
Avi Vandersluis ◽  
Alexandra Colquhoun ◽  
Alex Kiss ◽  
Neil Fleshner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Aerobic Exercise ◽  
Cancer Progression ◽  
Prostate Cancer Progression ◽  
Westernized Diet
Sign in / Sign up

Export Citation Format

Share Document